Abstract：
OBJECTIVE: The effect of multidisciplinary therapy conducted at the sarcoma center of our hospital was examined to determine whether therapy undertaken here improved the prognosis of patients with soft-tissue sarcoma.
METHODS: The clinical findings and prognoses of patients treated before the establishment of the sarcoma center (72 patients from April 2016 to March 2018) and those treated after (155 patients from April 2018 to March 2021) were compared.
RESULTS: The mean number of patients increased from 36.0 to 51.7 per year after the establishment of the sarcoma center. The proportion of patients with stage IV disease also increased from 8.3% to 12.9% after establishment of the sarcoma center. The 3-year survival rate of patients, considering all stages, decreased from 80.0% to 78.3% after establishment of the sarcoma center rather than showing an increase. The 3-year survival rate of patients with stage II and III disease increased from 78.6% to 84.7%, and that of stage III patients with retroperitoneal sarcoma increased from 70.0% to 86.7% after establishment of the sarcoma center. However, no statistically significant difference was observed in the survival curves.
CONCLUSIONS: The establishment of a sarcoma center has contributed to centralizing treatment for soft-tissue sarcoma. Multidisciplinary therapy at sarcoma centers may improve the prognosis of patients with soft-tissue sarcomas.
METHODS: The clinical findings and prognoses of patients treated before the establishment of the sarcoma center (72 patients from April 2016 to March 2018) and those treated after (155 patients from April 2018 to March 2021) were compared.
RESULTS: The mean number of patients increased from 36.0 to 51.7 per year after the establishment of the sarcoma center. The proportion of patients with stage IV disease also increased from 8.3% to 12.9% after establishment of the sarcoma center. The 3-year survival rate of patients, considering all stages, decreased from 80.0% to 78.3% after establishment of the sarcoma center rather than showing an increase. The 3-year survival rate of patients with stage II and III disease increased from 78.6% to 84.7%, and that of stage III patients with retroperitoneal sarcoma increased from 70.0% to 86.7% after establishment of the sarcoma center. However, no statistically significant difference was observed in the survival curves.
CONCLUSIONS: The establishment of a sarcoma center has contributed to centralizing treatment for soft-tissue sarcoma. Multidisciplinary therapy at sarcoma centers may improve the prognosis of patients with soft-tissue sarcomas.
摘要：
目的：对我院肉瘤中心进行的多学科治疗的效果进行了检查，以确定在此进行的治疗是否改善了软组织肉瘤患者的预后。
方法：比较肉瘤中心建立前治疗的患者（2016年4月至2018年3月72例患者）和建立后治疗的患者（2018年4月至2021年3月155例患者）的临床表现和预后。
结果：肉瘤中心成立后，患者平均每年从36.0增加到51.7。建立肉瘤中心后，IV期疾病患者的比例也从8.3％增加到12.9％。患者的3年生存率,考虑到所有阶段，肉瘤中心建立后从80.0%下降到78.3%，而不是增加。II期和III期患者的3年生存率从78.6%上升到84.7%,建立肉瘤中心后，III期腹膜后肉瘤患者的比例从70.0％增加到86.7％。然而,在存活曲线中没有观察到统计学上的显著差异。
结论：肉瘤中心的建立有助于软组织肉瘤的集中治疗。肉瘤中心的多学科治疗可以改善软组织肉瘤患者的预后。
方法：比较肉瘤中心建立前治疗的患者（2016年4月至2018年3月72例患者）和建立后治疗的患者（2018年4月至2021年3月155例患者）的临床表现和预后。
结果：肉瘤中心成立后，患者平均每年从36.0增加到51.7。建立肉瘤中心后，IV期疾病患者的比例也从8.3％增加到12.9％。患者的3年生存率,考虑到所有阶段，肉瘤中心建立后从80.0%下降到78.3%，而不是增加。II期和III期患者的3年生存率从78.6%上升到84.7%,建立肉瘤中心后，III期腹膜后肉瘤患者的比例从70.0％增加到86.7％。然而,在存活曲线中没有观察到统计学上的显著差异。
结论：肉瘤中心的建立有助于软组织肉瘤的集中治疗。肉瘤中心的多学科治疗可以改善软组织肉瘤患者的预后。
